Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | PIM1 | P11309 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
| ▸ | MST1R | Q04912 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 4/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22120086 | 0.86 | PARP1 (0.54) | PARP1PARP10PARP11 | |
| SCHEMBL30905974 | 0.86 | PARP1 (0.54) | PARP1PARP10PARP11 | |
| SCHEMBL25810413 | 0.82 | LPL (0.32) | — | |
| SCHEMBL508291 | 0.76 | ALDH1A1 (0.37) | PIK3CAAURKA | |
| SCHEMBL31707905 | 0.76 | ALDH1A1 (0.37) | PIK3CAAURKA | |
| SCHEMBL23611827 | 0.74 | PRMT5 (0.35) | — | |
| SCHEMBL22663357 | 0.74 | LPL (0.33) | CLK4PIM1ROCK1GSK3BNTRK1 | |
| SCHEMBL29496110 | 0.72 | JAK2 (0.37) | ROCK2 | |
| SCHEMBL2364747 | 0.72 | JAK2 (0.37) | ROCK2 | |
| SCHEMBL1016712 | 0.72 | DRD2 (0.41) | CDK5GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731608-A1 | ISOINDOLINONE-CONTAINING PARP INHIBITORS AND METHODS OF USE | Valo Health, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4634186-A1 | 2,6,9-TRISUBSTITUTED PURINES | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| WO-2025038747-A1 | MODIFIED THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2025-02-20 | — | — | WO | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | DRAIG THERAPEUTICS LTD (GB) | 2024-12-26 | — | — | US | disclosed |
| WO-2024261709-A1 | ISOINDOLINONE-CONTAINING PARP INHIBITORS AND METHODS OF USE | VALO HEALTH, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-11-10 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| WO-2011044157-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2099798-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008065199-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
| US-20060287370-A1 | Isoindolinone kinase inhibitors | CURTIN MICHAEL L | 2006-12-21 | — | — | US | disclosed |
| US-7129260-B2 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | CLK4 3502/4885PIM1 378/4885ROCK1 4108/4885 |
| US-20060287370-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | CLK4 604/4885PIM1 286/4885ROCK1 315/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | CLK4 3502/4885PIM1 378/4885ROCK1 4108/4885 |
| US-12441744-B2 | 2,6,9-trisubstituted purines | CDK2, CDK1, CCNT2 | CLK4 560/4885PIM1 860/4885ROCK1 1513/4885 |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | CLK4 560/4885PIM1 860/4885ROCK1 1513/4885 |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | GABRA5, GABRB3, GABRA3 | CLK4 3408/4885PIM1 4808/4885ROCK1 2345/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | CLK4 4480/4885PIM1 64/4885ROCK1 1387/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | CLK4 2344/4885PIM1 602/4885ROCK1 946/4885 |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | CLK4 604/4885PIM1 286/4885ROCK1 315/4885 |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABL1, LCK, MAP3K7 | CLK4 604/4885PIM1 286/4885ROCK1 315/4885 |
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | MAP3K7, MAP3K5, MAP3K20 | CLK4 483/4885PIM1 331/4885ROCK1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.